The Brain in Kidney Disease (BRINK) Cohort Study: Design and Baseline Cognitive Function

Anne M. Murray, Elizabeth J. Bell, David E. Tupper, Cynthia S. Davey, Sarah L. Pederson, Elizabeth M. Amiot, Kathleen M. Miley, Lauren McPherson, Brooke M. Heubner, David T. Gilbertson, Robert N. Foley, Paul E. Drawz, Yelena Slinin, Rebecca C. Rossom, Kamakshi Lakshminarayan, Prashanthi D Vemuri, Clifford R Jr. Jack, David S Knopman

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: The Brain in Kidney Disease (BRINK) Study aims to identify mechanisms that contribute to increased risk for cognitive impairment in patients with chronic kidney disease (CKD). We describe the rationale, design, and methods of the study and report baseline recruitment and cognitive function results. Study Design: Longitudinal observational cohort study of the epidemiology of cognitive impairment in CKD. The primary aim is to characterize the association between (1) baseline and incident stroke, white matter disease, estimated glomerular filtration rate (eGFR), inflammation, microalbuminuria, and dialysis initiation and (2) cognitive decline over 3 years in a CKD cohort with a mean eGFR2. Setting & Participants: Community-dwelling participants 45 years or older recruited from 4 health systems into 2 groups: reduced eGFR, defined as eGFR2 (non-dialysis dependent), and control, defined as eGFR≥60mL/min/1.73m2. Predictor: eGFR group. Outcomes: Performance on cognitive function tests and structural brain magnetic resonance imaging. Measurements: Sequential cognitive and physical function testing, serum and urine biomarker measurement, and brain magnetic resonance images over 3 years. Results: Of 554 participants, mean age was 69.3 years; 333, 88, and 133 had eGFRs2, respectively. Mean eGFR in reduced-eGFR participants was 34.3mL/min/1.73m2. Baseline cognitive performance was significantly associated with eGFR in all domains except language. Participants with eGFRs2 performed significantly worse than those with eGFRs≥30mL/min/1.73m2 on tests of memory, processing speed, and executive function. Participants with reduced eGFRs overall scored worst on the Immediate Brief Visual-Spatial Memory Test-Revised. Limitations: Healthy cohort bias, competing risk for death versus cognitive decline. Conclusions: Cognitive function was significantly worse in participants with eGFRs2. Future BRINK analyses will measure risk factors for cognitive decline using the longitudinal data.

Original languageEnglish (US)
JournalAmerican Journal of Kidney Diseases
DOIs
StateAccepted/In press - Jun 19 2015

Fingerprint

Kidney Diseases
Glomerular Filtration Rate
Cognition
Cohort Studies
Brain
Chronic Renal Insufficiency
Independent Living
Leukoencephalopathies
Executive Function
Observational Studies
Longitudinal Studies
Dialysis
Epidemiology
Magnetic Resonance Spectroscopy
Language
Biomarkers
Stroke
Magnetic Resonance Imaging
Cognitive Dysfunction
Urine

Keywords

  • Attention
  • Brain aging
  • Chronic kidney disease (CKD)
  • Cognitive impairment
  • Estimated glomerular filtration rate (eGFR)
  • Executive function
  • Language
  • Memory
  • Neuropsychological testing
  • Processing speed
  • Renal function
  • Stroke
  • Structural brain magnetic resonance imaging
  • Study design

ASJC Scopus subject areas

  • Nephrology

Cite this

The Brain in Kidney Disease (BRINK) Cohort Study : Design and Baseline Cognitive Function. / Murray, Anne M.; Bell, Elizabeth J.; Tupper, David E.; Davey, Cynthia S.; Pederson, Sarah L.; Amiot, Elizabeth M.; Miley, Kathleen M.; McPherson, Lauren; Heubner, Brooke M.; Gilbertson, David T.; Foley, Robert N.; Drawz, Paul E.; Slinin, Yelena; Rossom, Rebecca C.; Lakshminarayan, Kamakshi; Vemuri, Prashanthi D; Jack, Clifford R Jr.; Knopman, David S.

In: American Journal of Kidney Diseases, 19.06.2015.

Research output: Contribution to journalArticle

Murray, AM, Bell, EJ, Tupper, DE, Davey, CS, Pederson, SL, Amiot, EM, Miley, KM, McPherson, L, Heubner, BM, Gilbertson, DT, Foley, RN, Drawz, PE, Slinin, Y, Rossom, RC, Lakshminarayan, K, Vemuri, PD, Jack, CRJ & Knopman, DS 2015, 'The Brain in Kidney Disease (BRINK) Cohort Study: Design and Baseline Cognitive Function', American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2015.11.008
Murray, Anne M. ; Bell, Elizabeth J. ; Tupper, David E. ; Davey, Cynthia S. ; Pederson, Sarah L. ; Amiot, Elizabeth M. ; Miley, Kathleen M. ; McPherson, Lauren ; Heubner, Brooke M. ; Gilbertson, David T. ; Foley, Robert N. ; Drawz, Paul E. ; Slinin, Yelena ; Rossom, Rebecca C. ; Lakshminarayan, Kamakshi ; Vemuri, Prashanthi D ; Jack, Clifford R Jr. ; Knopman, David S. / The Brain in Kidney Disease (BRINK) Cohort Study : Design and Baseline Cognitive Function. In: American Journal of Kidney Diseases. 2015.
@article{db1094eed0e148f28e9517d2eab314f8,
title = "The Brain in Kidney Disease (BRINK) Cohort Study: Design and Baseline Cognitive Function",
abstract = "Background: The Brain in Kidney Disease (BRINK) Study aims to identify mechanisms that contribute to increased risk for cognitive impairment in patients with chronic kidney disease (CKD). We describe the rationale, design, and methods of the study and report baseline recruitment and cognitive function results. Study Design: Longitudinal observational cohort study of the epidemiology of cognitive impairment in CKD. The primary aim is to characterize the association between (1) baseline and incident stroke, white matter disease, estimated glomerular filtration rate (eGFR), inflammation, microalbuminuria, and dialysis initiation and (2) cognitive decline over 3 years in a CKD cohort with a mean eGFR2. Setting & Participants: Community-dwelling participants 45 years or older recruited from 4 health systems into 2 groups: reduced eGFR, defined as eGFR2 (non-dialysis dependent), and control, defined as eGFR≥60mL/min/1.73m2. Predictor: eGFR group. Outcomes: Performance on cognitive function tests and structural brain magnetic resonance imaging. Measurements: Sequential cognitive and physical function testing, serum and urine biomarker measurement, and brain magnetic resonance images over 3 years. Results: Of 554 participants, mean age was 69.3 years; 333, 88, and 133 had eGFRs2, respectively. Mean eGFR in reduced-eGFR participants was 34.3mL/min/1.73m2. Baseline cognitive performance was significantly associated with eGFR in all domains except language. Participants with eGFRs2 performed significantly worse than those with eGFRs≥30mL/min/1.73m2 on tests of memory, processing speed, and executive function. Participants with reduced eGFRs overall scored worst on the Immediate Brief Visual-Spatial Memory Test-Revised. Limitations: Healthy cohort bias, competing risk for death versus cognitive decline. Conclusions: Cognitive function was significantly worse in participants with eGFRs2. Future BRINK analyses will measure risk factors for cognitive decline using the longitudinal data.",
keywords = "Attention, Brain aging, Chronic kidney disease (CKD), Cognitive impairment, Estimated glomerular filtration rate (eGFR), Executive function, Language, Memory, Neuropsychological testing, Processing speed, Renal function, Stroke, Structural brain magnetic resonance imaging, Study design",
author = "Murray, {Anne M.} and Bell, {Elizabeth J.} and Tupper, {David E.} and Davey, {Cynthia S.} and Pederson, {Sarah L.} and Amiot, {Elizabeth M.} and Miley, {Kathleen M.} and Lauren McPherson and Heubner, {Brooke M.} and Gilbertson, {David T.} and Foley, {Robert N.} and Drawz, {Paul E.} and Yelena Slinin and Rossom, {Rebecca C.} and Kamakshi Lakshminarayan and Vemuri, {Prashanthi D} and Jack, {Clifford R Jr.} and Knopman, {David S}",
year = "2015",
month = "6",
day = "19",
doi = "10.1053/j.ajkd.2015.11.008",
language = "English (US)",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The Brain in Kidney Disease (BRINK) Cohort Study

T2 - Design and Baseline Cognitive Function

AU - Murray, Anne M.

AU - Bell, Elizabeth J.

AU - Tupper, David E.

AU - Davey, Cynthia S.

AU - Pederson, Sarah L.

AU - Amiot, Elizabeth M.

AU - Miley, Kathleen M.

AU - McPherson, Lauren

AU - Heubner, Brooke M.

AU - Gilbertson, David T.

AU - Foley, Robert N.

AU - Drawz, Paul E.

AU - Slinin, Yelena

AU - Rossom, Rebecca C.

AU - Lakshminarayan, Kamakshi

AU - Vemuri, Prashanthi D

AU - Jack, Clifford R Jr.

AU - Knopman, David S

PY - 2015/6/19

Y1 - 2015/6/19

N2 - Background: The Brain in Kidney Disease (BRINK) Study aims to identify mechanisms that contribute to increased risk for cognitive impairment in patients with chronic kidney disease (CKD). We describe the rationale, design, and methods of the study and report baseline recruitment and cognitive function results. Study Design: Longitudinal observational cohort study of the epidemiology of cognitive impairment in CKD. The primary aim is to characterize the association between (1) baseline and incident stroke, white matter disease, estimated glomerular filtration rate (eGFR), inflammation, microalbuminuria, and dialysis initiation and (2) cognitive decline over 3 years in a CKD cohort with a mean eGFR2. Setting & Participants: Community-dwelling participants 45 years or older recruited from 4 health systems into 2 groups: reduced eGFR, defined as eGFR2 (non-dialysis dependent), and control, defined as eGFR≥60mL/min/1.73m2. Predictor: eGFR group. Outcomes: Performance on cognitive function tests and structural brain magnetic resonance imaging. Measurements: Sequential cognitive and physical function testing, serum and urine biomarker measurement, and brain magnetic resonance images over 3 years. Results: Of 554 participants, mean age was 69.3 years; 333, 88, and 133 had eGFRs2, respectively. Mean eGFR in reduced-eGFR participants was 34.3mL/min/1.73m2. Baseline cognitive performance was significantly associated with eGFR in all domains except language. Participants with eGFRs2 performed significantly worse than those with eGFRs≥30mL/min/1.73m2 on tests of memory, processing speed, and executive function. Participants with reduced eGFRs overall scored worst on the Immediate Brief Visual-Spatial Memory Test-Revised. Limitations: Healthy cohort bias, competing risk for death versus cognitive decline. Conclusions: Cognitive function was significantly worse in participants with eGFRs2. Future BRINK analyses will measure risk factors for cognitive decline using the longitudinal data.

AB - Background: The Brain in Kidney Disease (BRINK) Study aims to identify mechanisms that contribute to increased risk for cognitive impairment in patients with chronic kidney disease (CKD). We describe the rationale, design, and methods of the study and report baseline recruitment and cognitive function results. Study Design: Longitudinal observational cohort study of the epidemiology of cognitive impairment in CKD. The primary aim is to characterize the association between (1) baseline and incident stroke, white matter disease, estimated glomerular filtration rate (eGFR), inflammation, microalbuminuria, and dialysis initiation and (2) cognitive decline over 3 years in a CKD cohort with a mean eGFR2. Setting & Participants: Community-dwelling participants 45 years or older recruited from 4 health systems into 2 groups: reduced eGFR, defined as eGFR2 (non-dialysis dependent), and control, defined as eGFR≥60mL/min/1.73m2. Predictor: eGFR group. Outcomes: Performance on cognitive function tests and structural brain magnetic resonance imaging. Measurements: Sequential cognitive and physical function testing, serum and urine biomarker measurement, and brain magnetic resonance images over 3 years. Results: Of 554 participants, mean age was 69.3 years; 333, 88, and 133 had eGFRs2, respectively. Mean eGFR in reduced-eGFR participants was 34.3mL/min/1.73m2. Baseline cognitive performance was significantly associated with eGFR in all domains except language. Participants with eGFRs2 performed significantly worse than those with eGFRs≥30mL/min/1.73m2 on tests of memory, processing speed, and executive function. Participants with reduced eGFRs overall scored worst on the Immediate Brief Visual-Spatial Memory Test-Revised. Limitations: Healthy cohort bias, competing risk for death versus cognitive decline. Conclusions: Cognitive function was significantly worse in participants with eGFRs2. Future BRINK analyses will measure risk factors for cognitive decline using the longitudinal data.

KW - Attention

KW - Brain aging

KW - Chronic kidney disease (CKD)

KW - Cognitive impairment

KW - Estimated glomerular filtration rate (eGFR)

KW - Executive function

KW - Language

KW - Memory

KW - Neuropsychological testing

KW - Processing speed

KW - Renal function

KW - Stroke

KW - Structural brain magnetic resonance imaging

KW - Study design

UR - http://www.scopus.com/inward/record.url?scp=84951914396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951914396&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2015.11.008

DO - 10.1053/j.ajkd.2015.11.008

M3 - Article

C2 - 26744128

AN - SCOPUS:84951914396

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

ER -